DoH and ADIO partner with unilabs to establish advanced analytical laboratory for clinical research
By working hand-in-hand with ADIO and Unilabs, the Department remains dedicated to providing innovative treatments and breakthrough solutions in the UAE and around the world
Abu Dhabi, UAE: The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and the Abu Dhabi Investment Office (ADIO) have signed a Memorandum of Understanding (MoU) with Unilabs Pharma Solutions, a subsidiary of leading international provider of diagnostic services Unilabs, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW). Under the agreement, the parties aim to develop a state-of-the-art analytical laboratory as part of Abu Dhabi's recently launched Health, Endurance, Longevity, and Medicine (HELM) cluster, a pioneering hub for biotechnology, MedTech and digital health innovation.
In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of Department of Health – Abu Dhabi (DoH) and Carsten Hojlund, Group Chief Financial Officer at Unilabs. The MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of Health Life Sciences Sector at DoH, Mohammed Daoud, Cluster General Manager of Unilabs Middle East and Dr. Fatma Al Mulla, Head of the Health, Endurance, Longevity, and Medicine cluster at ADIO.
Under the MoU, the parties seek to drive advancements in drug development, clinical trials and screening, aligning with DoH's efforts to position the Emirate as a global life sciences hub and an incubator for responsible healthcare innovation. Through working hand in hand with Unilabs and ADIO, the Department remains dedicated to providing innovative treatments and breakthrough solutions in the UAE and around the world.
Dr. Asma Ibrahim Al Mannaei, Executive Director of Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said: " In Abu Dhabi, we are strategically advancing health and life sciences through driving investment in transformative technologies, diagnostics and treatments to elevate healthcare outcomes while fostering sustainable economic growth. Working alongside prestigious partners such as the Abu Dhabi Investment Office and Unilabs Pharma Solutions, DoH remains steadfast in our commitment to positioning the Emirate as a leading destination for life science, accelerating innovation and expanding access to cutting-edge health services and treatment for communities locally and globally. This state-of-the-art analytical laboratory exemplifies the Department's proactive vision to establish a dynamic, future-ready healthcare ecosystem that anticipates challenges, embraces adaptability and prioritises the evolving needs of all communities, ensuring a resilient, healthier and innovation-driven tomorrow.'
By leveraging the combined expertise of all three partners, the analytical laboratory's advanced technology and operational capabilities will be deployed through a potential greenfield project, enhancing the economic value of high-impact intellectual property. Further, support mechanisms will be explored to maximise the initiative's long-term economic benefits, including high-value job creation, supply chain localisation and increased investment in cutting-edge healthcare infrastructure.
Dr. Fatma Al Mulla, Head of the Health, Endurance, Longevity, and Medicine Cluster at the Abu Dhabi Investment Office (ADIO), stated: "This partnership is a clear example of how we are embedding advanced capabilities across the life sciences value chain, creating a launchpad for innovation that begins with research and extends through to real-world impact. By investing in early-stage analytical infrastructure, Abu Dhabi is not only strengthening its role in the global life sciences landscape but is also laying the foundation for impactful intellectual property generation, high-value job creation and knowledge transfer. This initiative exemplifies the cluster's ambition to ensure that healthcare innovation contributes directly to economic acceleration, technological advancement and the development of a sustainable, knowledge-based economy —one that is anchored in Abu Dhabi, and connected to the world.'
Mohammed Daoud, Cluster General Manager of Unilabs Middle East:"We are proud to be part of this strategic project and look forward to exploring collaboration opportunities. With our cutting-edge pharmaceutical analysis technologies, internationally accredited laboratory tests, and strong capacity to train local talent, Unilabs is the ideal partner to help strengthen integration with the existing healthcare system. Abu Dhabi offers an exceptional environment for such transformative initiatives, thanks to the tireless commitment of government entities and their continuous support for innovation. We are excited about the potential to establish an advanced analytical centre in Abu Dhabi. The emirate boasts a state-of-the-art infrastructure and a clear vision for growth in the healthcare and innovation sectors. We very much look forward to exploring mutually beneficial ways to bring our expertise and support Abu Dhabi's efforts to become a major hub for drug development in the region. This centre would be Unilabs Pharma Solutions' first investment in pharmaceutical solutions in the Middle East."
ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being.
ADGHW 2025 offers complimentary visitor passes that grant access to the event's Start Up Zone, live stage sessions and exhibition hall featuring 150 global leaders in health.
About the Department of Health – Abu Dhabi (DoH):
The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual.
About the Abu Dhabi Investment Office (ADIO):
The Abu Dhabi Investment Office (ADIO) is the government vehicle responsible for accelerating Abu Dhabi's growth and enabling the emirate's economic transformation. Through comprehensive support services, ADIO enables both local and foreign investors to shape industries of the future set to transform liveability, technology, resources and value-added services. Initiatives focused on regional tourism and retail development, as well as public-private partnerships, ensure that community well-being is at the centre of Abu Dhabi's economic transformation. With a robust network of investors, strong collaboration with key stakeholders and a global presence, ADIO is committed to empowering those who invest with Abu Dhabi to make a lasting global impact.
About Unilabs:
Unilabs is a leading international provider of diagnostic services offering a complete range of laboratory, pathology, genetics and imaging services to patients across four continents. With over 13,000 people in 14 markets, Unilabs invests heavily in technology, equipment, and people – using digital technologies in its state-of-the-art laboratories and imaging institutes – to improve the lives of close to 100 million people every year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
a day ago
- Al Etihad
Global paediatric, orthopaedic experts to offer treatment, consultation in Abu Dhabi this month
9 June 2025 22:01 SAMIHAH ZAMAN (ALETIHAD)A trio of global experts in paediatrics and a top orthopaedic surgeon are offering care and consultations in Abu Dhabi this month, the Department of Health – Abu Dhabi (DoH) has doctors are headed to the emirate as part of the DoH's Visiting Physicians Programme, which aims to extend advanced healthcare services to residents.'The Department of Health – Abu Dhabi welcomes top-tier doctors from around the world to the Emirate during June, offering exceptional healthcare services through the Visiting Physicians Programme,' the DoH - Abu Dhabi's health regulator - announced in a post on its social media platforms. Visiting Physicians: June (From left to right) Dr. Kaveh Asadi, Dr. Matthew Dobbs, and Professor Oliver Berborgt are offering care in Abu Dhabi this June Dr. Kaveh Asadi, paediatric neurosurgery consultant at St Mary Hospital, Paley Institute in Florida, US, is one of the eminent doctors who will see patients in Abu Dhabi. He will be available at Burjeel Medical City's Paley Middle East Centre between June 9-13, and also on June 23. Dr. Asadi specialises in selective dorsal rhizotomy for the treatment of cerebral palsy, intra dural tumour treatment, craniofacial surgery, and tethered cord Matthew Dobbs, paediatric orthopaedic consultant at St. Mary Hospital in the US, will also join Dr. Asadi at the Burjeel Medical City between June 9-13. Dr. Dobbs' areas of specialisation include the treatment of congenital and developmental foot, lower extremity deformities, flatfoot deformities, cerebral palsy spasticity, and Oliver Verborgt, head of services for orthopaedics at Belgium's Monica Hospital, will also offer his expert care at the Tarmeem Hospital in Abu Dhabi on June 27 and 28. Prof Verborgt specialises in shoulder and elbow surgeries and reconstruction, and in the management of sports-related DoH has urged patients to directly contact the respective hospitals to book appointments. Earlier this month, Dr. Annique Hogan, an award-winning physician and paediatrician at Children's Hospital of Philadelphia, also saw patients at Sheikh Khalifa Medical City, sharing her expert advice on the care of children with complex medical needs. Complex Care Close to Home The DoH's Visiting Physicians Programme breaks new ground every month, ensuring care for complex medical conditions within Abu Dhabi. Since its launch in 2021, the programme has partnered with leading global health institutions to offer treatment and surgeries for patients in the region while eliminating the need for them to travel of December 2024, a total of 3,277 patients with rare and complex medical conditions had received care in Abu Dhabi as part of the to the DoH, the top five specialties in which visiting physicians offer care include paediatric haematology for bone marrow transplants; plastic surgery for lymphedema and brachial plexus; adult orthopaedic surgeries for complex ankle, foot, shoulder, hand and scoliosis; paediatric orthopaedic care for limb lengthening and limb deformities; and ophthalmology. The programme has also allowed for knowledge transfer, the enhancement of local healthcare expertise and post-surgical rehabilitation care, and the improvement of health outcomes throughout Abu Dhabi. Source: Aletihad - Abu Dhabi
Khaleej Times
03-06-2025
- Khaleej Times
Shookra Clinics launches in Dubai, ushering in new era of high-tech regenerative aesthetics
Dubai's wellness sector has welcomed a major innovation with the launch of Shookra Clinics, a state-of-the-art regenerative aesthetics and longevity center that blends biotechnology, precision diagnostics, and advanced cellular therapies. Touted as a first-of-its-kind concept in the region, Shookra Clinics introduces a 4-phase medical protocol that leverages AI-powered diagnostics, stem cell-based treatments, and personalised longevity programmes — placing it at the intersection of healthtech, aesthetics, and preventative medicine. The clinic's protocol begins with in-depth testing — including AI-based skin, hair, and scalp scans, genetic and bloodwork profiling, and biological age assessments — to create an individualised treatment roadmap. Subsequent phases integrate cutting-edge procedures like stem cell infusions, exosome therapy, PRP, mesotherapy, and energy-based technologies such as Morpheus8 and fractional lasers. Unlike traditional aesthetic offerings focused on surface-level results, Shookra's data-led model is built for measurable transformation and long-term biological optimisation. "This is a protocol-based, diagnostic-first system designed to rejuvenate from the inside out," said a clinic spokesperson. "It reflects the future of wellness - personalised, preventative, and regenerative." Operating on an exclusive membership model, each Shookra client receives dedicated support through a medical supervisor and concierge advisor. AI-driven dashboards track progress quarterly, adjusting skincare and supplement plans based on ongoing diagnostics. This long-term approach emphasises biological resilience and internal rejuvenation, not just external enhancement. With investment from Terra-Invest and a business strategy focused on high-margin, loyalty-based care, Shookra is already preparing for regional expansion — with new branches planned across the UAE and Saudi Arabia in response to growing demand for regenerative healthcare among affluent consumers. Shookra's launch comes as the Middle East's wellness market undergoes rapid evolution. According to MEA Wellness Market Reports, the regional aesthetic and longevity sector is projected to exceed $5.4 billion by 2030. Shookra's blend of advanced diagnostics, personalised treatment pathways, and a scalable infrastructure position it to capitalise on this growth - offering a next-generation solution for consumers seeking proactive, data-informed wellness. With further plans to integrate with AI wellness platforms and roll out biologically tailored product lines, Shookra aims to set a new global benchmark in aesthetic medicine - not just offering services but creating a full operating system for aging well.
Filipino Times
31-05-2025
- Filipino Times
DOH: Recent mpox cases in PH still from mild, self-limiting variant
All recently reported mpox cases in the country were caused by a milder strain of the virus, the Department of Health (DOH) clarified. 'There are LGUs reporting mpox, but I have to declare, all of them are mpox clade II,' said Health Secretary Ted Herbosa, referring to the same variant that caused confirmed cases in 2023 and 2024. He described this strain as 'very mild and self-limiting.' Clade II differs from the more infectious clade Ib, which was responsible for the mpox surge in parts of Africa and was declared a global health emergency by the World Health Organization last year. Given the current situation, Herbosa said there will be no new nationwide restrictions. 'We have an mpox task force. We are having surveillance,' he said, assuring the public that authorities are closely monitoring cases to prevent the entry of the more severe clade Ib. In recent weeks, mpox cases have been reported in parts of southern Philippines, particularly in Davao del Sur and Compostela in Davao de Oro, prompting local governments to enforce health measures such as mask-wearing and physical distancing. Davao City, however, denied online rumors of any community lockdown following an increase in confirmed mpox cases, which have now reached six. Mpox, previously known as monkeypox, is an infectious disease that spreads primarily through close physical contact, including sexual contact, and is not airborne. 'It's very important to isolate, and once recovered, hopefully, there will be no complications,' Herbosa said. The Philippines recorded 52 mpox cases in 2024, including one death, which the DOH said may have been due to complications from the disease.
